2016 Abstracts of SAKK and Collaborating Groups

European Lung Cancer Conference 2016, Geneva

Poster discussion

Gautschi O. et al. Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: results of the expanded SAKK19/09 trial.

Poster

Rothschild SI et al. SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.

103. Jahreskongress der Schweizerischen Gesellschaft für Chirurgie, Lugano

Oral presentations

Hamel C. et al. Clinical function after total mesorectal excision and rectal replacement. Primary results of the Swiss prospective randomized multicenter trial (SAKK 40/04) comparing side-to-end anastomosis, colon-J-pouch and straight coloanal anastomosis.

Ribi K. et al. Quality of life after total mesorectal excision and rectal replacement. Early results of the Swiss prospective randomized multicenter trial (SAKK 40/04) comparing side-to-end anastomosis, colon-J-pouch and straight coloanal anastomosis.

AACR Annual Meeting, New Orleans

Poster


ASCO Annual Meeting 2016, Chicago

Poster sessions

Rothschild SI et al. SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.


Abstract

Heukamp LC. et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology: NEOplus and NEOliquid.